PSCH Invesco S&P Smallcap Health Care Etf
- 41.870
- -0.440-1.04%
Select Medical Unit Concentra Files for U.S. IPO
$100 Invested In This Stock 15 Years Ago Would Be Worth $1,800 Today
Ensign Group (NASDAQ:ENSG) has outperformed the market over the past 15 years by 9.01% on an annualized basis producing an average annual return of 21.55%. Currently, Ensign Group has a market capital
4 Constructive Medical Devices Stocks - BTIG
AMD To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Susquehanna
Oppenheimer Maintains Outperform on Tandem Diabetes Care, Raises Price Target to $58
Oppenheimer analyst Steven Lichtman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and raises the price target from $47 to $58.
Stocks With the Highest and Lowest Liquidity - Goldman Sachs
Alkermes to Present Promising Narcolepsy Treatment Data at Annual Sleep Conference
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024PRNewswire– Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibran
6 Analysts Assess Alkermes: What You Need To Know
Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table encapsulates their recent ratings
Alkermes Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/23/2024 98.27% Cantor Fitzgerald $43 → $48 Maintains Overweight 05/02/2024 44.57% HC Wainwright & Co. →
Jim Cramer Offers His Take On Corning, Calls This Healthcare Stock A 'Terrific Spec'
On CNBC's "Mad Money Lightning Round," Jim Cramer said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a "terrific spec" and he recommended buying the same.On May 9, Recursion Pharmaceuticals reporte
Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)
Glaukos (NYSE:GKOS) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below provides a concise overview of recent r
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Glaukos Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 19.99% Citigroup $120 → $130 Maintains Buy 05/06/2024 15.38% Jefferies $84 → $125 Upgrades Hold
Tandem Diabetes Care Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 7.76% Stifel $45 → $55 Maintains Buy 05/06/2024 7.76% Barclays $39 → $55 Maintains Overweight 0
XPeng Posts Strong Results, Joins Larimar Therapeutics, Transcat And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 50 points on Tuesday.Shares of XPeng Inc. (NYSE:XPEV) rose sharply during Tuesday's session after the company reported better-th
Tandem Diabetes Care, Guardion Health, GT Biopharma Among Healthcare Movers
Prestige Consumer Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 -0.09% DA Davidson $65 → $65 Maintains Neutral 06/26/2023 -7.78% DA Davidson → $60 Reiterates N
Earnings Call Summary | Prestige Consumer Healthcare(PBH.US) Q4 2024 Earnings Conference
The following is a summary of the Prestige Consumer Healthcare Inc (PBH) Q4 2024 Earnings Call Transcript:Financial Performance:Prestige's Q4 performance fell short due to supply chain pressures and u
Cisco, Prestige Consumer Healthcare And 3 Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:Wall Street expects Cisco Systems, Inc. (NASDAQ:CSCO) to report qu
Prestige Consumer Shares Are Trading Lower After the Company Reported Worse-than-expected Q4 Financial Results and Issued Weak Guidance.
Prestige Consumer Shares Are Trading Lower After the Company Reported Worse-than-expected Q4 Financial Results and Issued Weak Guidance.